XML 64 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Reportable Segment Information (Tables)
 12 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Information About Domestic and International Operations

Information about Ashland’s domestic and international operations follows. Ashland has no operations in any individual international country or single customer that represented more than 10% of sales in 2021, 2020 or 2019.

 

 

Sales to external
customers

 

 

Net assets
(liabilities)

 

 

Property, plant and
equipment - net

 

(In millions)

 

2021

 

 

2020

 

 

2019

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

United States

 

$

637

 

 

$

623

 

 

$

674

 

 

$

1,520

 

 

$

1,919

 

 

$

1,092

 

 

$

1,147

 

International

 

 

1,474

 

 

 

1,393

 

 

 

1,474

 

 

 

1,232

 

 

 

1,117

 

 

 

335

 

 

 

338

 

 

 

$

2,111

 

 

$

2,016

 

 

$

2,148

 

 

$

2,752

 

 

$

3,036

 

 

$

1,427

 

 

$

1,485

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment for the years ended September 30, 2021, 2020 and 2019.

Ashland Global Holdings Inc. and Consolidated Subsidiaries

 

 

 

 

 

 

 

 

 

Reportable Segment Information

 

 

 

 

 

 

 

 

 

Years Ended September 30

 

 

 

 

 

 

 

 

 

(In millions)

 

2021

 

 

2020

 

 

2019

 

Sales

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

737

 

 

$

708

 

 

$

732

 

Personal Care & Household

 

 

592

 

 

 

615

 

 

 

651

 

Specialty Additives

 

 

655

 

 

 

589

 

 

 

654

 

Intermediates and Solvents

 

 

178

 

 

 

129

 

 

 

160

 

Intersegment sales (a)

 

 

(51

)

 

 

(25

)

 

 

(49

)

 

 

$

2,111

 

 

$

2,016

 

 

$

2,148

 

Equity income

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

—

 

 

$

—

 

 

$

—

 

Personal Care & Household

 

 

—

 

 

 

—

 

 

 

—

 

Specialty Additives

 

 

—

 

 

 

—

 

 

 

—

 

Intermediates and Solvents

 

 

—

 

 

 

—

 

 

 

—

 

 

 

$

—

 

 

$

—

 

 

$

—

 

Other income (expense)

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

—

 

 

$

1

 

 

$

—

 

Personal Care & Household

 

 

2

 

 

 

—

 

 

 

(1

)

Specialty Additives

 

 

—

 

 

 

1

 

 

 

—

 

Intermediates and Solvents

 

 

—

 

 

 

—

 

 

 

—

 

Unallocated and Other

 

 

7

 

 

 

6

 

 

 

5

 

 

 

$

9

 

 

$

8

 

 

$

4

 

Equity and other income

 

$

9

 

 

$

8

 

 

$

4

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

130

 

 

$

123

 

 

$

114

 

Personal Care & Household (b)

 

 

73

 

 

 

(296

)

 

 

85

 

Specialty Additives (b)

 

 

61

 

 

 

(132

)

 

 

18

 

Intermediates and Solvents

 

 

35

 

 

 

(10

)

 

 

28

 

Unallocated and Other

 

 

(118

)

 

 

(148

)

 

 

(159

)

 

 

$

181

 

 

$

(463

)

 

$

86

 

 

(In millions)

 

2021

 

 

2020

 

 

2019

 

Depreciation expense

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

36

 

 

$

33

 

 

$

33

 

Personal Care & Household

 

 

39

 

 

 

41

 

 

 

42

 

Specialty Additives

 

 

66

 

 

 

62

 

 

 

98

 

Intermediates and Solvents

 

 

12

 

 

 

13

 

 

 

10

 

Unallocated and Other

 

 

1

 

 

 

2

 

 

 

5

 

 

 

$

154

 

 

$

151

 

 

$

188

 

Amortization expense (c)

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

28

 

 

$

27

 

 

$

28

 

Personal Care & Household

 

 

42

 

 

 

36

 

 

 

37

 

Specialty Additives

 

 

19

 

 

 

19

 

 

 

21

 

Intermediates and Solvents

 

 

1

 

 

 

1

 

 

 

3

 

Unallocated and Other

 

 

—

 

 

 

1

 

 

 

—

 

 

 

$

90

 

 

$

84

 

 

$

89

 

EBITDA (d) (e)

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

194

 

 

$

183

 

 

$

175

 

Personal Care & Household

 

 

154

 

 

 

(219

)

 

 

164

 

Specialty Additives

 

 

146

 

 

 

(51

)

 

 

137

 

Intermediates and Solvents

 

 

48

 

 

 

4

 

 

 

41

 

Unallocated and Other

 

 

(117

)

 

 

(145

)

 

 

(154

)

 

 

$

425

 

 

$

(228

)

 

$

363

 

Additions to property, plant and equipment

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

27

 

 

$

51

 

 

$

54

 

Personal Care & Household

 

 

7

 

 

 

13

 

 

 

20

 

Specialty Additives

 

 

67

 

 

 

59

 

 

 

57

 

Intermediates and Solvents

 

 

2

 

 

 

5

 

 

 

7

 

Unallocated and Other

 

 

2

 

 

 

5

 

 

 

9

 

 

 

$

105

 

 

$

133

 

 

$

147

 

 

(In millions)

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

Life Sciences

 

$

1,945

 

 

$

1,974

 

Personal Care & Household (f)

 

 

1,145

 

 

 

939

 

Specialty Additives

 

 

1,636

 

 

 

1,666

 

Intermediates and Solvents

 

 

160

 

 

 

161

 

Unallocated and Other (g)

 

 

1,726

 

 

 

2,137

 

 

 

$

6,612

 

 

$

6,877

 

Property, plant and equipment - net

 

 

 

 

 

 

Life Sciences

 

$

451

 

 

$

439

 

Personal Care & Household

 

 

159

 

 

 

205

 

Specialty Additives

 

 

651

 

 

 

656

 

Intermediates and Solvents

 

 

61

 

 

 

72

 

Unallocated and Other

 

 

105

 

 

 

113

 

 

 

$

1,427

 

 

$

1,485

 

 

 

 

 

 

 

 
(a)
Intersegment sales from Intermediates and Solvents are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.
(b)
Includes a fixed asset impairment of $3 million related to Personal Care & Household and a capital project impairment of $10 million related to Specialty Additives for the year ended September 30, 2021.
(c)
Includes amortization of $4 million for the year ended September 30, 2019 related to land-use-rights associated with other non-current assets.
(d)
Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and net income (loss) on divestitures. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
(e)
Includes $39 million of accelerated depreciation for the year ended September 30, 2019.
(f)
See Note B for acquired assets associated with the Schülke personal care business on April 30, 2021.
(g)
Includes assets held for sale.